Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Size and Structure of Viral Genomes

Size and Structure of Viral Genomes

Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Machine Learning Framework for Cancer Prognostics: Integrating Temporal and Immune Gene Dynamics via ARIMA-CNN.

Biomedicines·2025

Same author

Hepatitis B core-related antigen kinetics predict spontaneous HBeAg seroclearance in chronic hepatitis B patients.

Journal of gastroenterology·2025

Same author

Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.

Hepatology (Baltimore, Md.)·2025

Same author

Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap.

Rheumatology (Oxford, England)·2025

Same author

Interleukin 27 (IL-27) productions in the liver microenvironment confer an immunosuppressive role and enhance hepatitis B viral persistence.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2025

Same author

Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold.

Gut·2025

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

Primary cell models of HIV latency.

Hung-Chih Yang¹

¹Department of Microbiology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. hcyang88@ntu.edu.tw

Current Opinion in HIV and AIDS

|January 19, 2011

Summary

Developing in-vitro primary cell models of human immunodeficiency virus (HIV) latency is crucial for understanding and eradicating the virus. These models aid in discovering drugs to purge the latent HIV reservoir in CD4+ T cells.

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Humanized NOD/SCID/IL2rγ^null (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Humanized NOD/SCID/IL2rγ^null (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Area of Science:

Virology
Immunology
Cell Biology

Background:

HIV latency is a major barrier to viral eradication.
Developing accurate in-vitro models of HIV latency in primary cells remains challenging.
Resting CD4+ T cells are key reservoirs for latent HIV.

Purpose of the Study:

To review recent advancements in in-vitro primary cell models of HIV latency.
To discuss the application of these models in HIV eradication research.
To highlight their potential for drug discovery and screening.

Main Methods:

Review of recent scientific literature on HIV latency models.
Analysis of different approaches to generate latently HIV-infected primary CD4+ T cells.
Evaluation of the suitability of these models for biochemical studies and drug screening.

Main Results:

Several novel in-vitro primary cell models of HIV latency have been developed.
These models can authentically recapitulate quiescent, latently infected CD4+ T cells.
The models are suitable for biochemical investigations and high-throughput drug screening.

Conclusions:

Progress in primary cell models significantly advances the study of HIV latency mechanisms.
These models provide a platform for identifying drugs to eliminate the latent HIV reservoir.
Further research using these models can lead to novel therapeutic strategies for HIV eradication.